



TRANSFORMING PREVENTATIVE HEALTHCARE THROUGH MICROBIOME INTELLIGENCE

Canada's first insurance-reimbursed gut microbiome platform

Dr. Nikitha Kendyala, PhD
Chief Executive Officer
Nucliq Biologics Inc.,

nucliqbio.ca | mygutcheck.ca

WHO WE SERVE — HIGH-NEED POPULATIONS



Gastric & Digestive Health

The Gut Health Gap

- 0.5 Billion in world and 1 in 5 Canadians live with IBS or chronic digestive issues
- \$18B annual burden from GI disorders in Canada alone
- 60% of patients report unsatisfactory diagnosis journeys
- Microbiome imbalance linked to depression, obesity & autoimmune disease



Women's Hormonal Health

Across Every Life Stage

- 8 in 10 women in world - hormone imbalance
- The estrobolome regulates oestrogen — directly microbiome-dependent
- 75M+ women affected by hormonal disorders (PCOS, endometriosis, menopause)
- Puberty · Fertility · Perimenopause — each stage shifts the microbiome
- Only 4% of health R&D funding targets female-specific conditions

A TEAM BUILT FOR GLOBAL IMPACT IN GUT HEALTH : COFOUNDERS



Dr. Nikitha Kendyala, PhD

CEO/Co-founder

Nikitha Kendyala is a biochemist-turned-entrepreneur with over 15 years of experience in cancer and molecular biology research. She co-founded Nucliq Biologics in 2019 and has since scaled the company from two founders to a 14-member team operating across Canada and India.



Dr. Purvikalyan Pallegar, PhD

CTO/Co-founder

Purvikalyan Pallegar is a molecular biologist with over 14 years of experience in plant and microbial biology. Since co-founding Nucliq Biologics in 2019, he has led the development of the company's core technologies, including the Gutcheck™ and Gutcheck VIVO™ platforms, enabling accessible microbiome testing in Canada.

A NEW ERA OF PREVENTATIVE HEALTH

Nucliq: Pioneering a Microbiome Intelligence Platform

We transform microbiome testing into actionable health insights and a growing biological dataset

Why Now

Preventative care reimbursement

AI-driven health analytics

Breakthrough microbiome science

What the Platform Delivers

- At-home microbiome test kit
- AI-driven health insights
- Practitioner-guided recommendations
- Continuous microbiome data generation



Health Canada approval for the collection device MDEL license for Class I

A NEW ERA OF PREVENTATIVE HEALTH



Gastric & Digestive Health

Gutcheck

Comprehensive gut health test for all

- Gutcheck – Microbiome testing for gastrointestinal and metabolic health (IBS, gut disorders, metabolic conditions)
- Symptomatic management along side with the treatment
- 87% of patients report satisfactory symptom connection
- Microbiome balance helps manage prevention of depression, obesity & autoimmune disease



Women's Hormonal Health

Gutcheck VIVO

The world's only gut test built for women's hormonal health across every life stage

- Testing can support personalized diet, lifestyle, and practitioner-guided strategies for metabolic and hormonal wellness for women affected by hormonal disorders (PCOS, endometriosis, menopause).
- Insights support menopause wellness, vaginal/urogenital health awareness, bone-metabolic health, and personalized nutrition.
- This helps to fill the data gap of microbiome research connecting hormones and health issues for women.

T O D A Y

PROVEN TRACTION . PROPRIETARY DATA . VALIDATION.

Proven sales momentum, strong customer reception, and pipeline validation for microbiome therapeutics

SALES TRACTION

\$1M+

Total Revenue

Since Sep 2022

5,000+

Gut Profiles Tested

Real-world customer dataset

140,000+

Phenotypic Data Points

28+ Variables per customer

50%

Y-o-Y Growth

Sustained trajectory

97%

of D2C Forecast

Delivered in Q1 2026



STRONG CONSUMER VALIDATION

★★★★★ 4.9 / 5

Average customer rating



92%

Would highly recommend Gutcheck™ to others



88%

Reported actionable insights from results

***We started as a microbiome testing company.
Each customer is helping us build the data
infrastructure for a precision microbiome
platform.***

THE GAP IN TODAY'S MICROBIOME TESTING

CURRENT MARKET PROBLEMS

- ✗ No practitioner integration — results left uninterpreted
- ✗ Not covered by insurance — paid out-of-pocket only
- ✗ No structured follow-up care pathway
- ✗ Generic population benchmarks vs personalised guidance
- ✗ Consumer-only model misses corporate wellness opportunity



GUTCHECK/VIVO SOLUTION

- ✓ Practitioner-in-the-loop for guided, actionable results
- ✓ Insurance-enabled pathway via MGA & broker channels
- ✓ Longitudinal monitoring with care plan integration
- ✓ Life-stage personalisation (hormonal, gut, metabolic)
- ✓ B2B deployment via employers & benefit programs


FROM INSIGHTS TO DISCOVERY: NUCLIQ’S END-TO-END ADVANTAGE

Competitive Factor/Companies	Nucliq: Gutcheck™ + VIVO	Viome	Ombre / Injoy	GI-MAP	Nucliq Geographic Advantage
Market Positioning	Diagnostics-to-discovery platform for gut, women’s health, and future therapeutics validation	Consumer wellness + AI nutrition	Consumer gut wellness	Clinical/pathogen-focused stool test	Canada, India, UAE, USA: expandable platform, not just a one-time test
Women’s Health Focus	VIVO, hormones, estrobolome, PMS/PCOS, menopause	Limited women’s health focus	None	Pathogen-focused, not wellness-focused	India: PCOS/metabolic demand. UAE: premium women’s wellness. Canada/USA: insurer and clinic adoption
Access & Affordability	Preferred pricing, B2B channels, insurer pathway	Higher consumer pricing	Lower cost but limited depth	Higher cost, clinician-only	India: scalable affordability. Canada: reimbursable pathway. UAE/USA: premium clinic/employer programs
B2B & Insurance Channels	Medavie Blue Cross, clinics, providers, wellness centres, employers	Mostly DTC	Mostly DTC	Clinical channel	Canada: first-mover insurer validation. India: wellness-centre scale. UAE/USA: employer and premium clinic channels

MARKET OPPORTUNITY (GI + WOMEN'S HEALTH)



\$4T+ North American chronic care spend - large and growing preventative healthcare market
Millions suffer from IBS, metabolic disease, and hormone-related conditions.



Supported by the high growth rates in microbiome diagnostics (17.5% CAGR) and strategic market entry in high-demand regions like North America.

BUSINESS MODEL & DISTRIBUTION CHANNELS



Multi-channel revenue model spanning D2C, clinical partnerships, insurance, and enterprise

REVENUE STREAMS



Direct-to-Consumer (D2C)

Gutcheck™ & Gutcheck™ VIVO sold direct via e-commerce. Foundation channel since 2022 launch.

Launched 2022



B2B Clinical Partnerships

25+ private clinics and healthcare providers prescribing and recommending the test to patients.

25+ Partners



Insurance Reimbursement

Blue Cross coverage drives 20% revenue lift, lowering customer acquisition friction.

+20% Revenue



Enterprise Agreements

Medavie Enterprise Agreement signed with joint initiatives launched for population health.

Medavie Signed

Strategic Partners & Channel Reach

Trusted by leading insurers, clinics, and wellness centres



Blue Cross

Insurance Coverage



MGA_other Insurance

Enterprise Agreement



25+ Clinics

Canada Network



Wellness Centres

India Partnerships



Healthcare Providers

Referral Network



Research Partners

Microbiome Studies

Active in Canada & India • Expanding to additional global markets

INDIAN MARKET SCOPE & OPPORTUNITY

Large, underserved market for precision gut-health & microbiome solutions

Turning India's chronic-disease epidemic into a 1.4-billion-person microbiome opportunity — already proven in market.

Proven Traction (In India Pilot phase)

500+

KITS SOLD @ Single Wellness Center

~\$100K CAD

Revenue generated


~\$200 CAD

Average kit price

Why it matters: a single, zero-marketing-spend pilot already validated willingness-to-pay at Canadian-comparable prices, proof this is a repeatable playbook, not a one-off.

THE OPPORTUNITY

A \$19B+ global category, anchored in the largest chronic-disease burden on earth



TAM

\$19.1B → \$40.6B

Global personalized nutrition & preventive gut-health testing, 2025→2030 (16.4% CAGR)

SAM

~\$3.5-4B by 2030

India nutraceuticals/preventive wellness + corporate wellness + clinical diagnostic channels

SOM

\$20-35M run-rate (Yr 5)

0.5–1% capture across B2C, wellness-center, corporate & clinical channels

Sources: ICMR-INDIAB (Lancet 2023); JAMA Network Open 2023 (ICMR-PCOS); The Business Research Company, Personalized Nutrition Market 2025-2030; IMARC, India Nutraceuticals & Corporate Wellness Markets; Global Wellness Institute 2025 Country Rankings. SAM/SOM are illustrative estimates.

TRACTION, REVIEWS & STRATEGIC VALIDATION



Proven sales momentum, strong customer reception, and pipeline validation for microbiome therapeutics

SALES TRACTION

\$1M+

Total Revenue

Since Sep 2022

50%

Y-o-Y Growth

Sustained trajectory

10–20%

M-o-M Growth

Since Jan 2026

97%

of D2C Forecast

Delivered in Q1 2026

Customer Reception & Reviews 5000 customers

★★★★★ 4.9 / 5

Average customer rating

✓ 92%

Would recommend Gutcheck™ to others

✓ 88%

Reported actionable insights from results



LOIs & Microbiome Therapeutics Pipeline

Pipeline of signed Letters of Intent validating Nucliq's therapeutic potential



Research Institution LOIs

Microbiome therapeutic validation studies underway



Data Licensing Pipeline

Proprietary microbiome dataset for therapeutic R&D



Projected Future Revenue

Licensing & royalties contributing 25–35% by 2028

WHY RAISE NOW?

WE HAVE VALIDATED THE PLATFORM. CAPITAL UNLOCKS SCALE

The next phase transforms commercial traction and proprietary microbiome data into a scalable precision-health and therapeutic platform.

TARGET



*Every commercial test generates both
revenue and data.*

\$2M Seed / Pre-Series A

18-24 Month Growth Plan

*Accelerating Commercial Scale,
Global Expansion & Therapeutic Innovation*

Why Now?

- Commercially validated platform
- First insurer-covered microbiome testing program in North America
- Two differentiated products launched
- Growing proprietary microbiome dataset
- AI-enabled precision health platform
- Drug discovery pipeline already initiated

Investment Allocation

\$2,000,000



PARTNER WITH US TO BUILD THE FUTURE OF PRECISION HEALTH



Nucliq is not just selling products; we are
redefining precision medicine and unlocking a
healthier future



APPENDICES

A TEAM BUILT FOR GLOBAL IMPACT IN GUT HEALTH



Dr. Shazia Janwari, PhD

Machine Learning Engineer

Shazia has been the ML engineer since the inception of the company, she works on building AI-driven solutions to translate microbiome and health data into actionable insights. With a PhD from the Indian Institute of Science (IISc), Shazia brings a strong foundation in computational modeling and data science, along with experience in applying machine learning to real-world problems.



Farida Samad-zada, MSc

Sr Bioinformatician


Farida Samadzada is a bioinformatics and genomics specialist with experience in next-generation sequencing and data analysis. Since 2020, she has been contributing to research and applied projects focused on understanding complex biological systems through computational approaches. With a strong foundation in genomic data analysis and microbiome research, Farida brings valuable expertise in translating sequencing data into meaningful biological insights.



Sadie Whitehorne, BSc

Software developer

Sadie Whitehorne is a Software Developer at Nucliq Biologics with a background in computer science from Memorial University of Newfoundland. She contributes to building and supporting the company's digital platforms, helping translate complex health and microbiome data into accessible, user-friendly tools.



Dr. Luke Bown, PhD

Lab Operations Manager


. With a strong grounding in both wet-lab science and data interpretation, Luke enhances Nucliq's ability to generate high-quality, defensible insights that underpin its long-term vision in diagnostics and microbiome-derived therapeutics.



Sean Kennedy

Sales/Partnerships - Fractional

Sean has over 2 decades of experience in working alongside emerging tech companies, offering tailored solutions that propel them towards sustainable success. From identifying target markets and crafting effective go-to-market strategies to facilitating partnerships with industry leaders.



Mahmoud Hassan, BSc. Pharma, MBA

Marketing Manager

Mahmoud is a health-tech marketing Manager with over 15 years of experience in the pharmaceutical industry, bringing together health insight, commercial acumen, and digital expertise. With a diversified education in Pharmaceutical Sciences, MBA, and software development, he bridges science, strategy, and innovation to create meaningful value.

A TEAM BUILT FOR GLOBAL IMPACT IN GUT HEALTH-ADVISORS



Dr. Lourdes Pena Castillo, PhD

Professor-Scientific Advisor

Departments of Biology and Computer Science (jointly appointed) at Memorial University Faculty of Science. Throughout her academic career, she has developed and/or applied artificial intelligence or machine learning methods in various areas such as biomedical sciences, games, and augmented virtuality.



Dr. Balakishan Gorityala, PhD

CTO/Co-founder-Biotech Advisor

Polyamyna Nanotech Inc. Dr. Gorityala holds tremendous experience in science driven commercialization apart from drawing from over two decades of experience in biotechnology research, Dr. Gorityala has held pivotal roles, including Scientist at CanAm Bioresearch Inc. and Research Associate at the University of Manitoba, Canada.



Dr. Rajinder Singh Lamba

Holistic Wellness -India

With over 40 years of entrepreneurial and spiritual mastery, Dr. Rajinder Singh Lamba is a rare blend of wisdom, success, humility, and heart. Advocate and Key wellness representative for Gutcheck products in wellness centres in India. Facilitating strategic partnerships in Wellness across India.



Dr. Vishnun Rao Veerapaneni,

Clinical Advisor-India

MBBS, Diploma in Child Health, MD Chest and Tuberculosis, FCCP. He is a well known Pulmonologist and has 36 years of experience in this field. As an Advisor to Nucliq Biologics, he provides strategic clinical guidance to research initiatives at the intersection of microbiome science, immunology, and respiratory health.

What Will \$2M Achieve?

2025 Revenue

\$275K

Current



2026 Run Rate

>\$480K ARR

Already achieved



18-Month Target

\$2.5–3M

Annualized Revenue

 **Canada**

Expand beyond Medavie
Target: 5+ insurers
Sun Life · Manulife
Canada Life · GreenShield

 **India**

Hospital & corporate wellness
Preventive health clinics
Distributor partnerships
Pediatric & women's health

 **UAE**

Commercial launch
Insurance reimbursement
Daman Insurance target
Strategic HCP partnerships

 **USA**

GutCheck + VIVO launch
Functional medicine clinics
Dietitians & GI specialists
D2C e-commerce

10–12 Strategic Hires

VP Commercial · US BD Director · India & UAE Leads · 3
Science Sales · Customer Success · Bioinformatics Scientist ·
AI Engineer · Regulatory Affairs

12,000–15,000 Customers

From ~2,500 today → largest proprietary microbiome
dataset across North American preventive care

MicroterraAI Expansion

Clinical decision support · Practitioner dashboard ·
Predictive health models · Insurance reporting · Multi-
omics integration

THE NUCLIQ VISION: TRANSFORMING MICROBIOME INSIGHTS INTO PRECISION HEALTH SOLUTIONS

Microbiome in
Prevention and
therapeutics



2019

Founded



Gutcheck™

2022

Gutcheck™

VIVQ

Gutcheck Analysis Platform

2025



Data-Mining Platform


Nucliq's Microterra AI uncovers
therapeutic breakthroughs across
disease areas

2028



Gut-brain
Therapeutic
Partnerships

2035



INNOVATION & ENTERPRISE VALUE CREATION

Product Pipeline

GutCheck Mini — Pediatric Launch

Infants & children · Pediatric hospitals · Pediatricians · Schools · Insurance

Insurance Expansion

Canada: 5 insurers (targets) · UAE: Daman reimbursement · Employer wellness & enterprise contracts

R&D Therapeutics

Microbiome-derived small molecules & peptides · Gut-brain axis · Gut-lung axis · Women's health

IP Strategy

2 international patent filings targeted · Novel microbiome-derived therapeutic molecules · AI-enabled biomarker & precision prediction platform

Milestone Timeline

Q3 2026

- USA commercial launch
- India expansion begins
- Insurer discussions (active)

Q4 2026

- GutCheck Mini launch
- Clinical partnerships formalized
- MicroterraAI v2 upgrade

Q1 2027

- Patent #1 filed
- US distribution channel live
- New Canadian insurer onboarded

Q2 2027

- Patent #2 filed
- Daman UAE reimbursement target
- US\$2.5–3M revenue run rate